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Specific effect of a dopamine partial 
agonist on counterfactual learning: 
evidence from Gilles de la Tourette 
syndrome
Alexandre Salvador1,2, Yulia Worbe3, Cécile Delorme3, Giorgio Coricelli4, Raphaël Gaillard2, 
Trevor W. Robbins5, Andreas Hartmann3 & Stefano Palminteri  1,6,7
The dopamine partial agonist aripiprazole is increasingly used to treat pathologies for which other 
antipsychotics are indicated because it displays fewer side effects, such as sedation and depression-like 
symptoms, than other dopamine receptor antagonists. Previously, we showed that aripiprazole may 
protect motivational function by preserving reinforcement-related signals used to sustain reward-
maximization. However, the effect of aripiprazole on more cognitive facets of human reinforcement 
learning, such as learning from the forgone outcomes of alternative courses of action (i.e., 
counterfactual learning), is unknown. To test the influence of aripiprazole on counterfactual learning, 
we administered a reinforcement learning task that involves both direct learning from obtained 
outcomes and indirect learning from forgone outcomes to two groups of Gilles de la Tourette (GTS) 
patients, one consisting of patients who were completely unmedicated and the other consisting of 
patients who were receiving aripiprazole monotherapy, and to healthy subjects. We found that whereas 
learning performance improved in the presence of counterfactual feedback in both healthy controls and 
unmedicated GTS patients, this was not the case in aripiprazole-medicated GTS patients. Our results 
suggest that whereas aripiprazole preserves direct learning of action-outcome associations, it may 
impair more complex inferential processes, such as counterfactual learning from forgone outcomes, in 
GTS patients treated with this medication.
Aripiprazole is a recently introduced antipsychotic medication with dopamine receptor partial agonist mecha-
nisms1. In schizophrenia patients, aripiprazole exhibited efficacy comparable to that of typical and atypical antip-
sychotics in the treatment of positive and negative symptoms as well as in the prevention of relapse2, 3. Its efficacy 
has also been demonstrated in other neurological disorders for which antipsychotics are indicated, such as Gilles 
de la Tourette syndrome (GTS)4, 5. Its tolerability is often considered superior to that of typical antipsychotics, and 
it is associated with fewer adverse side effects, such as extrapyramidal and metabolic syndromes6, 7. In GTS, arip-
iprazole is effective for suppressing tics while displaying a less severe side effect profile than dopamine receptor 
antagonists with regard to motivational deficits such as sedation and depressive reactions8. Due to this advanta-
geous cost-benefit trade-off, aripiprazole has become a widely prescribed treatment for schizophrenia and GTS.
Pharmacological studies in humans suggest that dopamine receptor antagonist-induced sedation and depres-
sive states may be the consequence of blunting of reward-related signals9, 10. For instance, reward-seeking behav-
iour and reward prediction errors encoded in the ventral striatum were reduced by haloperidol administration in 
healthy volunteers11. In contrast, both functions were preserved in GTS patients medicated with aripiprazole12. 
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These results are consistent with the idea that, as opposed to dopamine receptor antagonists, aripiprazole pre-
serves motivational functions via preserving reward-related signals.
Despite the observations described above, in humans, reinforcement learning is seldom solely based on learn-
ing from obtained outcomes (i.e., factual outcomes)13. In fact, human reinforcement learning often makes use of 
more abstract inferential processes, including learning from forgone outcomes14, 15. In other words, counterfac-
tual learning refers to the ability to learn not only from direct experience but also from hypothetical outcomes 
(the outcomes of the option that was not chosen). Previous neuroimaging studies have demonstrated that subjects 
take into account counterfactual feedback when it is available and have suggested that this form of learning could 
be underpinned by a dorsal prefrontal system16–18, despite the fact that some other studies have suggested that fac-
tual and counterfactual outcomes may be processed by the same neural system involving the ventral striatum19, 20. 
On the pharmacological level, a recent study that investigated counterfactual learning under a regimen of dietary 
depletion of serotonin and dopamine/noradrenalin precursors indicated that brain tracking of fictive prediction 
error might be sensitive to both dopamine and serotonin manipulation21.
Here, to characterize the effect of aripiprazole on counterfactual learning, we administered a recently 
developed behavioural task that contrasts learning from obtained and hypothetical outcomes to a group of 
medication-free GTS patients, a group of GTS patients with aripiprazole as their only medication, and matched 
healthy controls22. GTS patients represented an ideal model for this investigation because in this population we 
have already shown the beneficial effects of aripiprazole compared to a dopamine receptor antagonist in factual 
learning, that is, in learning from obtained outcomes (as opposed to counterfactual learning, which is learning 
from forgone outcomes)12. In addition, unlike many schizophrenic patients, GTS patients have relatively pre-
served cognitive efficiency23, 24. Finally, by investigating the effect of aripiprazole in a population that is commonly 
treated with this medication, our findings have direct clinical relevance.
Results
Demographic and psychometric results. All patients consulting at the GTS Reference Centre in Paris 
and meeting inclusion and exclusion criteria were screened for inclusion and offered participation in this study 
until we reached a figure of 40 patients (20 per treatment) giving consent to be included. The sample size for the 
current study was specified in the ethical approval and determined based on previous studies realized in our lab. 
Patients taking any medication other than aripiprazole (i.e., pimozide, risperidone, haloperidol, bromazepam or 
escitalopram) were not included in the final analysis. One patient did not complete the task and was also excluded 
from the analysis. This led to a final sample of 31 GTS patients (17 without any medication and 14 with aripipra-
zole monotherapy) (Table 1). In addition, 20 healthy controls obtained through advertising were included. Two 
significant differences were found when comparing the 3 groups: the number of years of study (F(2,48) = 3.2, 
p = 0.050) (although the results of the National Adult Reading Test (NART; F(2,46) = 1.2, p = 0.31), which 
measures verbal intelligence, did not differ among the groups) and the Beck Depression Inventory score (BDI, 
F(2,48) = 6.72, p = 0.0027). In addition, two scales showed marginal differences among the three groups: the 
Barratt Impulsiveness Scale (BIS-11; F(2,48) = 3.00, p = 0.059) and the Behavioural Inhibition/Behavioural 
Activation Scale (BIS/BAS; F(2,48) = 3.04, p = 0.057). However, there was no significant difference between the 
aripiprazole and unmedicated GTS groups on any demographic or psychometric scale or in disease severity index 
or measures of intelligence (all p > 0.2, two-sample t-test).
Behavioural results. Subjects performed a probabilistic instrumental learning task adapted from previous 
imaging studies22, 25. During the instrumental probabilistic learning task, the subjects were required to learn 
Controls Unmedicated Aripiprazole P2 P3
N 20 17 14
Age (m sd) 32.35 (13.36) 30.76 (10.33) 32.07 (11.52) 0.742 0.916
Sex = Female (%) 9 (45.0%) 4 (23.5%) 5 (35.7%) 0.729 0.395
Study (m sd) 14.40 (1.70) 13.24 (1.95) 12.79 (2.26) 0.557 0.050
NART (m sd) 308.50 (94.70) 262.81 (93.72) 267.00 (106.20) 0.911 0.310
YGTSS (m sd) — 37.87 (15.95) 31.14 (13.29) 0.230 —
Disease Duration 
(m sd) — 23.88 (10.95) 23.29 (11.81) 0.888 —
BDI (m sd) 1.75 (2.38) 6.59 (5.97) 7.07 (5.81) 0.822 0.003
STAI A (m sd) 47.60 (3.86) 47.76 (2.97) 47.08 (4.25) 0.606 0.874
STAI B (m sd) 47.71 (4.21) 50.29 (6.94) 51.09 (6.36) 0.762 0.272
BIS BAS (m sd) 44.90 (5.18) 41.41 (5.76) 40.36 (6.55) 0.637 0.059
BIS 11 (m sd) 60.40 (8.71) 65.94 (11.64) 69.29 (11.90) 0.437 0.057
Years on Aripip. 
(m sd) — — 5.75 (3.33) — —
Aripip. Dose, mg 
(m sd) — — 6.96 (6.88) — —
Table 1. Demographic characteristics and psychometric scales for participants by treatment group. The “p2” 
p-values correspond to the comparison between the unmedicated and aripiprazole groups (two- sample t-test). 
The “p3” p-values correspond to the comparison among all three groups (one-way analysis of variance).
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which stimuli had the greatest likelihood of resulting in an advantageous outcome through trial and error. The 
dependent variable was the subject’s accuracy; an “accurate” (or “correct”) choice was choice of the stimulus that 
is on average more rewarding or less punishing. Both feedback valence (reward vs. punishment) and feedback 
information (partial feedback vs. complete feedback) were manipulated using a within-subjects factorial design 
(Fig. 1A).
A preliminary analysis of variance (ANOVA) evaluating accuracy as a function of trial, feedback information, 
feedback valence and group (aripiprazole-treated GTS patients, unmedicated GTS patients, and controls) showed 
that there was a significant main effect of group (F(2,4864) = 14.5, p < 0.001), a significant main effect of trial 
number (F(1,4864) = 46.4, p < 0.001), and a significant main effect of feedback information (F(1,4864) = 23.7, 
p < 0.001), with an interaction effect of group with feedback information (F(2,4864) = 15.35, p < 0.001) but no 
main effect of feedback valence (F(1,4864) = 0.8, p > 0.3). Feedback valence was therefore excluded from the 
subsequent ANOVA analysis.
The final ANOVA, which evaluated accuracy as a function of trial, feedback information, and group, showed 
that there was a significant main effect of trial number on correct choice rate (F(1,2432) = 41.1, p < 0.001), indi-
cating that accuracy improved with learning (Fig. 2A). In addition, there was a significant main effect of feedback 
information (F(1,2432) = 21.0, p < 0.001) and of group (F(2,2432) = 12.9, p < 0.001), with a significant interac-
tion between group and feedback information (F(2,2432) = 13.6, p < 0.001), indicating that counterfactual feed-
back did not positively modulate the accuracy similarly in the three groups. The interaction effect of group and 
feedback information remained significant when years of study, BDI score, and BIS.11 or BIS.BAS impulsivity 
scores were included either individually or all together (F(2,2260) = 22.8, p < 0.001).
We then defined the « counterfactual gain » as the difference in accuracy between the complete feedback and 
the partial feedback conditions. A confirmatory ANOVA evaluating counterfactual gain as a function of group 
and trial showed a significant main effect of group (F(2,1216) = 17.9, p < 0.001), indicating that the groups ben-
efited differently from counterfactual information. There was no main effect of trial (F(1,1216) = 1.00, p = 0.3), 
indicating that the benefit from counterfactual information was present for the entire duration of the experiment. 
The effect of group remained significant when years of study, BDI score, and BIS.11 or BIS.BAS impulsivity scores 
were included either individually or all together (F(2,1130) = 25.1, p < 0.001).
Figure 1. Task. (A) Task contingencies and factorial design. The attribution of symbols to each condition was 
randomized across subjects. (B) Typical trials. A novel trial started after a fixation screen (500 ms). Subjects 
were required to select between the two options by pressing one of the corresponding two buttons with their 
left or right index fingers to select the leftmost or the rightmost option, respectively, within a 3000- ms time 
window. After the choice window, a red pointer appeared below the selected option for 500 ms. At the end of 
the trial, the options disappeared and the selected option was replaced by the outcome (“+0.5 €”, “0.0 €” or 
“−0.5 €”) for 3000 ms. In the complete information context, the outcome corresponding to the unchosen option 
(counterfactual) was also displayed.
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To assess the directionality of the critical ANOVA effects in a concise manner, we plotted and analysed the 
accuracy and the counterfactual gain averaged across trials. Accuracy in the complete feedback condition was 
significantly higher than accuracy in the partial feedback condition in both the control and unmedicated GTS 
groups (t(19) = −2.6, p < 0.05, and t(16) = −2.3, p < 0.05, respectively) but not in the aripiprazole GTS group 
(t(13) = 0.151, p = 0.882) (Fig. 2B). The average counterfactual gain was significantly higher in the control 
group and in the unmedicated group than in the aripiprazole group (8.3% controls versus 0.3% aripiprazole, 
t(31.5) = 2.2, p < 0.05; t-test 10.5% unmedicated versus 0.3% aripiprazole, t(23.3) = 2.1, p < 0.05). There was 
no difference in counterfactual gain between the control and unmedicated groups (t(29.3) = −0.4, p = 0.701) 
(Fig. 2C).
Interestingly, in the aripiprazole GTS group, we found a significant correlation between treatment dose and 
accuracy in the complete feedback condition (Spearman’s correlation test ρ = −0.66, p < 0.01), indicating that the 
higher the dose of atypical antipsychotic medication received, the lower the accuracy in the complete feedback 
condition. This correlation remained significant when the only patient with a 30-mg dose of aripiprazole was 
excluded (ρ = −0.57, p < 0.05) (Fig. 3). In contrast, treatment dose did not correlate with accuracy in the partial 
feedback condition (Spearman’s correlation test ρ = −0.47, p > 0.05).
To assess evidence in favour of the null hypothesis (i.e., the absence of counterfactual learning in the aripipra-
zole group), we performed a Bayesian equivalent of a t-test (see the Materials and Methods section). This analysis 
showed that the probability that the average counterfactual gain falls within a region of practical equivalence 
(i.e., ROPE: [−1.5%, 1.5%] interval) is small (4%) in both the unmedicated GTS group and in the control group, 
whereas this probability is 5.75 times larger (23%) in the aripiprazole group (Fig. 4@). This Bayesian approach 
provides evidence that the absence of counterfactual learning in the aripiprazole group does not arise from a lack 
of power in detecting it.
Finally, we analysed the reaction times using an ANOVA with trial, group and feedback information as factors 
(see Table 2). The ANOVA revealed a significant effect of trial, indicating that reaction time decreased across tri-
als (F(1,2432) = 17.8, p < 0.001). Feedback information and group did not affect reaction time (F(1,2432) = 0.08, 
p = 0.772 and F(2,2432) = 2.74, p = 0.064), nor did any of the interaction factors, indicating that reaction time was 
not modulated by the pathology or by the treatment.
Discussion
Using a probabilistic learning paradigm with factual (where subjects were informed only about the result of the 
chosen outcome) and counterfactual (where subjects were also informed about the result of the unchosen out-
come) feedback information conditions in healthy controls and aripiprazole-medicated and unmedicated GTS 
Figure 2. (A) Learning curves as a function of feedback information and group. The bold lines represent 
trial-by-trial average accuracy over the three sessions. The shaded areas between the thin lines represent 
the standard error of the mean with subject as the random factor. Light and dark grey represent partial and 
complete feedback conditions, respectively. (B) Average performance averaged across the 24 trials. (C) 
Average « counterfactual gain » (complete minus partial accuracy) (Co. = controls; Un. = unmedicated; 
Ar. = aripiprazole). #p < 0.05, one-sample t-test; *p < 0.05, two-sample t-test. The error bars represent the 
standard error of the mean with subject as the random factor.
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patients, we showed a specific effect of aripiprazole on counterfactual learning in the absence of any effect on 
factual learning in GTS patients receiving this medication.
All subjects performed significantly above chance level in the partial feedback condition, and accuracy did 
not differ across the groups. As previously shown, control subjects had higher accuracy in the complete feed-
back condition than in the partial feedback condition22, 26. However, in GTS patients, counterfactual learn-
ing was affected by medication status: unmedicated patients behaved similarly to healthy controls, whereas 
aripiprazole-medicated patients did not improve their performance in the presence of counterfactual feedback. 
Counterfactual learning, as implemented in our task, requires at least two component processes: a “peripheral” 
process, which corresponds to the fact that the complete feedback condition mobilizes additional attentional 
resources; and a “central” process, which corresponds to the integration of hypothetical prospects (“counterfac-
tuals”) in reinforcement learning27.
Figure 3. Correlation between aripiprazole dose and accuracy in the complete feedback context in all subjects 
(left) and excluding the subject with the highest dose (right).
Figure 4. Results of the Bayesian analysis for evidence in favour of the null hypothesis for the difference 
between accuracy in the complete and partial feedback conditions (i.e., « counterfactual gain ») for each group. 
ROPE is the region of practical equivalence, which was set at the level of 3% ([−1.5%, 1.5%]. “4% in ROPE” 
means that there is a 4% chance that the true average counterfactual gain lies within the region of the practical 
equivalence interval.
Condition
Accuracy (correct choice rate) Reaction time (seconds)
Rew./Par. Rew./Com. Pun./Par. Pun./Com. Rew./Par. Rew./Com. Pun./Par. Pun./Com.
Controls 0.68 ± 0.04 0.76 ± 0.04 0.68 ± 0.03 0.77 ± 0.04 1.16 ± 0.04 1.21 ± 0.06 1.37 ± 0.06 1.27 ± 0.06
Unmedic. 0.61 ± 0.05 0.74 ± 0.05 0.65 ± 0.04 0.72 ± 0.04 1.14 ± 0.06 1.16 ± 0.06 1.29 ± 0.06 1.28 ± 0.07
Aripipraz. 0.66 ± 0.05 0.64 ± 0.04 0.69 ± 0.03 0.70 ± 0.05 1.15 ± 0.06 1.16 ± 0.06 1.28 ± 0.06 1.27 ± 0.07
Table 2. Average behavioural data (mean ± s.e.m.).
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Was the effect of aripiprazole on counterfactual learning the hallmark of a specific impairment in counterfac-
tual reasoning or a consequence of reduced attention? Evidence against a nonspecific “peripheral” effect is the 
fact that baseline performance (as measured in the partial feedback condition) did not differ in the unmedicated 
and the aripiprazole GTS groups. If anything, average accuracy in the partial feedback condition was numerically 
higher in the aripiprazole GTS group than in the unmedicated GTS group (67.5% vs. 63.0%). Further evidence 
against the idea of a general attentional decrease is our finding that reaction times did not differ among the 
groups, indicating a similar level of engagement in the task for the subjects in all groups.
The preserved ability to learn from factual outcomes during aripiprazole treatment replicates previous work 
by Worbe and colleagues showing that aripiprazole did not affect probabilistic reward learning in GTS patients12. 
This characteristic of aripiprazole strikingly contrasts with the robust observation that dopamine antagonists 
blunt reward-related learning and performance9–11. Reduced counterfactual learning has been reported in nico-
tine addiction28. It may therefore be argued that this learning deficit may contribute to the increased likelihood of 
behavioural addictions, such as pathological gambling, in aripiprazole-medicated patients29 as well as the obser-
vation that aripiprazole increases cigarette smoking30.
The reduction in counterfactual learning in the aripiprazole group may come as a surprise because early stud-
ies proposed that, given its particular mechanism of action as a partial D2 agonist, aripiprazole would preserve 
or even improve high-level cognitive function through improved frontal dopamine release31, 32. However, later 
studies mitigated this expectation by showing no effect or even a deterioration in executive functions following 
aripiprazole administration33–39. Consistent with those findings, imaging studies failed to demonstrate an increase 
in frontal function and even showed reduced frontal metabolism associated with reduced performance in exec-
utive function tasks40–42. These contrasting findings on prefrontal dopamine might be linked to aripirazole dose; 
low-dose systemic aripiprazole (0.5 mg/kg) was shown to increase extracellular dopamine levels in the cortex, 
whereas high-dose aripiprazole (10 mg/kg) reduced dopamine levels in mice43, 44. This might explain why we find 
a detrimental effect on counterfactual learning that increases significantly with aripiprazole dose in our study.
Aripiprazole has binding affinity for both dopamine and serotonin receptors1. Its affinity for 5-HT1A recep-
tors in particular may provide an explanation for the apparent discrepancy between preserved factual learning 
and reduced counterfactual learning. Dopamine and serotonin have been associated with both automatic/reflex-
ive and deliberative/reflective reinforcement processing, which in our task could be incorporated into factual and 
counterfactual learning45–48. In particular, it has been shown that dietary depletion of tryptophan reduces the pro-
pensity to implement cognitive strategies in a reinforcement-learning task46, 49, and aripiprazole has been shown 
to reduce serotonin output in the prefrontal cortex and the dorsal raphe nucleus50. In the light of these findings, it 
may be argued that aripiprazole’s detrimental effect on counterfactual learning is mediated by an alteration in ser-
otoninergic neurotransmission. Aripiprazole would therefore have a specific pattern of effects on reinforcement 
learning that includes both preserved direct/factual learning due to its dopamine partial agonist property and 
reduced indirect/counterfactual learning due to its prefrontal serotonin disruption effect. Future studies in which 
specific dopaminergic and serotoninergic pharmacological agents are used are required to determine whether the 
effect of aripiprazole on counterfactual learning is mediated by its dopaminergic affinity or its serotonergic affinity 
or by a combination of the two.
Is the detrimental effect of aripiprazole on counterfactual learning specific to GTS patients or generaliza-
ble? The answer to this question is closely related to the mechanism through which aripiprazole blunts counter-
factual learning. GTS has been hypothesized to be dependent on a constitutive hyperactivity of dopaminergic 
neurotransmission51, 52. Positron emission tomography and post-mortem studies found evidence of increased 
dopamine concentration in both the striatum and the prefrontal cortex of GTS patients53–57. Thus, if the nega-
tive effect of aripiprazole on counterfactual learning is mediated by the dopamine system, the alterations of this 
neuromodulator that occur in GTS may preclude the generalizability of our result to other pathologies and to the 
general population. On the other hand, there is no current clear hypothesis and no replicated data implicating 
the serotoninergic system in GTS, with recent negative results58, 59. Thus, if the negative effect of aripiprazole on 
counterfactual learning is mediated by the serotonin system, it is less likely that it is specific to GTS patients.
Previous studies suggest that hyperactive reinforcement learning may contribute significantly to GTS symp-
toms60, 61. Assuming that positive and negative prediction errors are represented by phasic fluctuations in dopamin-
ergic transmission, we previously found that reinforcement learning in unmedicated GTS subjects was consistent 
with a functional hyperdopaminergia, both in terms of enhanced reward62 and reduced punishment learning63. 
These findings were obtained when reward-outcome contingencies were deterministic and unconscious as meas-
ured by post-test assessments of cue visibility and stimulus-reward associations and using a task that has been 
shown to rely specifically on the ventral striatum64. In contrast, our current results were obtained using a proba-
bilistic instrumental learning task that employs perfectly visible (therefore conscious) cues and recruits both the 
cortex (namely, the medial prefrontal cortices and the insula) and the ventral striatum22. In the present study, 
we found that unmedicated GTS patients performed equally well in the reward-seeking condition and in the 
punishment-avoidance condition. Taken together, our current and previous findings might suggest that in GTS 
excessive positive reinforcement occurs for implicit/unconscious (as opposed to explicit/conscious) learning pro-
cesses; this possibility could hypothetically be supported by the dependence of these two types of processes on dif-
ferent neural substrates (subcortical vs. prefrontal)65. This however is probably a partial explanation as in a slightly 
different paradigm in healthy subjects a valence-specific effect was obtained as a result of dopamine manipulation 
using consciously perceived cues9.
A potential limitation of our study is that it was observational, meaning that we included patients who 
were already either unmedicated or undergoing treatment with aripiprazole. The absence of group randomi-
zation raises the question that the effects attributed to aripiprazole may arise from pre-existing phenotypic 
between-group differences that determined the patients’ medication status. This is unlikely for several reasons. 
First, very few patients are either never or always medicated; thus, medication status fluctuates and does not 
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seem to be a patient-specific characteristic8. Second, to control as much as possible for this potential confound-
ing factor, we measured several clinical, psychological and cognitive parameters and compared them between 
groups. We ensured through a psychiatric interview that the included GTS subjects did not have comorbid psy-
chiatric diagnoses. We further measured a number of dimensions that could account for learning differences in 
our task, including general intelligence, disease severity, and cognitive and clinical dimensions, such as impul-
sivity, anxiety and depression, through rating scales. None of these dimensions differed significantly between 
aripiprazole-treated and unmedicated GTS patients; it is therefore unlikely that they could account for the reduc-
tion in counterfactual learning found in the aripiprazole group. Two of these dimensions, depression (BDI) and 
level of study, differed significantly between the control group and the two GTS groups, and impulsivity differed 
marginally. This, of course, does not affect our main claim regarding a difference between unmedicated and arip-
iprazole GTS patients. However, as a formal control, we included these dimensions as cofactors in the ANOVA 
analysis and found that the reported effects remained significant. To summarize, while the absence of group 
randomization is a methodological limitation that requires us to be cautious in concluding that the difference 
in counterfactual learning across groups is a specific result of treatment, we controlled for a number of potential 
confounding factors to make this conclusion as robust as possible.
Another potential limitation of our study is its relatively small sample size. While the number of partici-
pants analysed in each group is consistent with previous publications targeting reinforcement learning in GTS 
patients12, 62, 63, one could wonder whether the absence of difference in accuracy between the complete feedback 
and partial feedback conditions in the aripiprazole group might be due to a lack of power. However, the Bayesian 
analysis provided evidence that the absence of a difference in accuracy between the partial and complete feedback 
conditions specifically in the aripiprazole GTS group did not arise as the result of a lack of power.
To conclude, we demonstrated a negative effect of aripiprazole on counterfactual learning in a population of 
aripiprazole-medicated GTS patients. At present, it is unclear whether this finding can be generalized to other 
clinical populations and, most notably, to schizophrenic patients, for whom treatment with aripiprazole is becom-
ing increasingly popular. It is also unclear at this stage whether the observed effect is mediated by the dopaminer-
gic system or the serotoninergic system. Further research is needed to address these questions. Nonetheless, our 
findings shed new light on the characterization of the cognitive profile of aripiprazole in GTS patients treated with 
this medication and represent a first step in understanding the neuropharmacology of counterfactual learning.
Materials and Methods
Participants. The ethics committee of the Pitié-Salpêtrière Hospital approved the study (N° Promoteur: C11-
34; N° CPP: 97*19; N° ANSM: B121209-31). All participants gave written informed consent prior to participation 
in the study, and the study was conducted in accordance with the Declaration of Helsinki (1964).
All patients consulting at the GTS Reference Centre in Paris and meeting inclusion and exclusion criteria 
were screened for inclusion and offered participation in this study. They were examined by a multidisciplinary 
team experienced in GTS (AH and YW). Tic severity was rated on the Yale Global Tic Severity Scale66. Inclusion 
criteria for the patients were as follows: age above 18 and confirmed diagnosis of GTS fulfilling the DSM-5 crite-
ria. Aripiprazole-medicated GTS patients were on stable antipsychotic treatment for at least 4 weeks. Exclusion 
criteria included the co-occurrence of Axis I psychiatric disorders, including current major depressive disorder, 
current anxiety disorder, current or past psychotic disorder, substance abuse aside from nicotine, attention deficit 
disorder and obsessive- compulsive disorders. These pathologies were screened using both subsections of the 
Mini International Neuropsychiatry Inventory (MINI) and a clinical evaluation performed by a trained neu-
rologist who investigated the presence of diagnostic criteria for OCD or ADHD as detailed in the DSM-IV TR. 
Exclusion criteria also included any neurological or movement disorder other than tics as evaluated by a qualified 
neurologist before inclusion, as well as the use of any medication (including antidepressants and benzodiaze-
pines) in the unmedicated GTS group and the presence of any co-medication in the aripiprazole GTS group.
Healthy volunteers were recruited by hospital-based advertisements. The inclusion criterion for healthy volun-
teers was age over 18 years. The exclusion criteria were the same as for TS patients plus a personal history of tics 
and any concomitant treatment except contraceptive pills for women.
Behavioural task. The subjects performed a probabilistic instrumental learning task adapted from previous 
imaging studies22, 25. The subjects were first provided with written instructions, and these were reformulated orally 
if needed. Each participant first performed a short training session (16 trials) aimed at familiarizing the partici-
pant with the task’s timing and responses. The participant then performed three learning sessions.
The options were abstract symbols taken from the Agathodaimon font. Each session contained eight novel 
options grouped into four novel fixed pairs. The pairs of options were fixed so that a given option was always 
presented with the same other option. Thus, within each session, pairs of options represented stable choice con-
texts. Within sessions, each pair of options was presented 24 times for a total of 96 trials. The four option pairs 
corresponded to the four conditions (reward/partial, reward/complete, punishment/partial and punishment/
complete), and the four conditions were associated with different pairs of outcomes (reward contexts: winning 
0.5 € versus nothing; punishment contexts: losing 0.5 € versus nothing) and the provision of a different amount 
of information at feedback (partial or complete). In the partial feedback contexts, only the outcome regarding the 
chosen option was provided, whereas in the complete feedback contexts the outcomes of both the chosen and the 
unchosen option were provided (Fig. 1A). Within each pair, the two options were associated with the two possible 
outcomes with reciprocal probabilities (0.75/0.25 and 0.25/0.75). The subjects were informed that the aim of the 
task was to maximize their payoff and that only factual (and not counterfactual) outcomes counted. Between cues, 
the outcome probability was independent on a trial-by-trial basis, although it was anti-correlated on average. 
Thus, in a complete feedback trial, the subjects could observe the same outcome from both cues on 37.5% of trials 
and different outcomes from each cue on 62.5% of trials.
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Pairs of options were presented in a pseudo-randomized and unpredictable manner to each subject (inter-
mixed design). During each trial, one option was randomly presented on the left and one on the right side of a 
central fixation cross (Fig. 1B). The side on which a given option was presented was also pseudo-randomized 
such that a given option was presented an equal number of times on the left and on the right of the central cross.
Statistical analysis. From the learning task, we extracted accuracy. An “accurate” (or “correct”) choice 
occurs when the subject selects the most rewarding symbol in the reward-seeking context (i.e., the sym-
bols that yielded +0.5 € in 75% of cases and 0 € in 25% of cases) or selects the less punishing symbol in the 
punishment-avoidance context (i.e., the symbols that yielded 0 € in 75% of cases and −0.5 € in 25%). The central 
hypothesis regarding the effect of aripiprazole was assessed using a repeated measures ANOVA with group (« 
Controls », « Unmedicated », and « Aripiprazole ») as the between-subjects factor and trial (1:24), feedback 
valence (reward vs. punishment avoidance) and feedback information (partial feedback vs. complete feedback) 
as the within-subject factors. A specific effect of aripiprazole on counterfactual learning would result in a signif-
icant group x feedback information interaction. As a control, we performed an ANCOVA analysis that included 
additional psychometric measures (education, BDI, BIS.11 and BIS.BAS) as covariates. As an additional control, 
we performed the same ANOVA on reaction times. We also performed a confirmatory ANOVA on the “counter-
factual gain”, which was defined as the difference in the accuracy achieved in the complete and partial feedback 
contexts (a positive “counterfactual gain” indicates a beneficial effect of counterfactual feedback on performance).
To assess the directionality of the effect, we reported the average values of all dependent variables as well as the 
results of Student’s t-tests (two sample t-tests were used when comparing groups, and one sample t-test was used 
when comparing group-values to zero). A Welch-Satterthwaite approximation was used when the variance was 
not equal across the groups67. Correlations, in particular the correlation between treatment dose and accuracy, 
were computed using Spearman’s test. The significance level was set at 5%.
To assess evidence in favour of the null hypothesis (i.e., no difference in accuracy in the complete and partial 
feedback conditions), we performed a Bayesian equivalent of a t-test using Monte Carlo Markov chain analysis to 
compute the posterior probability of the difference in accuracy between the two feedback information conditions 
for each group. This analysis was conducted using the Bayesian Estimation Supersedes the t-Test (BEST) package 
version 0.4.0 in R statistical software with the BESTmcmc and plot.BEST functions. The region of practical equiv-
alence (ROPE) was set at 3%, meaning that we considered a difference included in the [−1.5%, 1.5%] interval to 
be too small to be considered relevant. Evidence for the null hypothesis was the probability that the actual dif-
ference between feedback information conditions lies in the ROPE for each group. This probability was assessed 
through Monte Carlo Markov chain analysis; 100 000 simulations were run for each test.
References
 1. Potkin, S. G. et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with 
schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60, 681–690 (2003).
 2. Pigott, T. A. et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 
26-week study. J Clin Psychiatry 64, 1048–1056 (2003).
 3. Kane, J. M. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective 
disorder. J Clin Psychiatry 63, 763–771 (2002).
 4. Kawohl, W., Schneider, F., Vernaleken, I. & Neuner, I. Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in 
adult patients. The world journal of biological psychiatry 10, 827–831 (2009).
 5. Neuner, I., Nordt, C., Schneider, F. & Kawohl, W. Effectiveness of aripiprazole in the treatment of adult Tourette patients up to 56 
months. Hum Psychopharmacol 27, 364–369 (2012).
 6. Citrome, L., Kalsekar, I., Baker, R. A. & Hebden, T. A review of real-world data on the effects of aripiprazole on weight and metabolic 
outcomes in adults. Curr Med Res Opin 30, 1629–1641 (2014).
 7. Stroup, T. S. et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to 
aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168, 947–956 
(2011).
 8. Hartmann, A. & Worbe, Y. Pharmacological treatment of Gilles de la Tourette syndrome. Neurosci Biobehav Rev 37, 1157–1161 
(2013).
 9. Frank, M. J., Seeberger, L. C. & O’reilly, R. C. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 306, 
1940–1943 (2004).
 10. Eisenegger, C. et al. Role of dopamine D2 receptors in human reinforcement learning. Neuropsychopharmacology 39, 2366–2375 
(2014).
 11. Pessiglione, M., Seymour, B., Flandin, G., Dolan, R. J. & Frith, C. D. Dopamine-dependent prediction errors underpin reward-
seeking behaviour in humans. Nature 442, 1042–1045 (2006).
 12. Worbe, Y. et al. Reinforcement learning and Gilles de la Tourette syndrome: dissociation of clinical phenotypes and pharmacological 
treatments. Arch Gen Psychiatry 68, 1257–1266 (2011).
 13. O’Doherty, J. P., Lee, S. W. & McNamee, D. The structure of reinforcement-learning mechanisms in the human brain. Current 
Opinion in Behavioral Sciences 1, 94–100 (2015).
 14. Coricelli, G. & Rustichini, A. Counterfactual thinking and emotions: regret and envy learning. Philosophical transactions of the 
Royal Society of London. Series B, Biological sciences 365, 241–247 (2010).
 15. Coricelli, G., Dolan, R. J. & Sirigu, A. Brain, emotion and decision making: the paradigmatic example of regret. Trends in cognitive 
sciences 11, 258–265 (2007).
 16. Boorman, E. D., Behrens, T. E. & Rushworth, M. F. Counterfactual choice and learning in a neural network centered on human 
lateral frontopolar cortex. PLoS biology 9, e1001093 (2011).
 17. Fischer, A. G. & Ullsperger, M. Real and fictive outcomes are processed differently but converge on a common adaptive mechanism. 
Neuron 79, 1243–1255 (2013).
 18. Koechlin, E. An evolutionary computational theory of prefrontal executive function in decision-making. Philosophical transactions 
of the Royal Society of London. Series B, Biological sciences 369 (2014).
 19. Kishida, K. T. et al. Subsecond dopamine fluctuations in human striatum encode superposed error signals about actual and 
counterfactual reward. Proceedings of the National Academy of Sciences of the United States of America 113, 200–205 (2016).
 20. Li, J. & Daw, N. D. Signals in human striatum are appropriate for policy update rather than value prediction. The Journal of 
neuroscience 31, 5504–5511 (2011).
www.nature.com/scientificreports/
9SCIENTIFIC RepoRts | 7: 6292  | DOI:10.1038/s41598-017-06547-8
 21. Tobia, M. J. et al. Neural systems for choice and valuation with counterfactual learning signals. NeuroImage 89, 57–69 (2014).
 22. Palminteri, S., Khamassi, M., Joffily, M. & Coricelli, G. Contextual modulation of value signals in reward and punishment learning. 
Nat Commun 6, 8096 (2015).
 23. Leckman, J. F. Tourette’s syndrome. Lancet 360, 1577–1586 (2002).
 24. Singer, H. S. Tourette’s syndrome: from behaviour to biology. Lancet Neurol 4, 149–159 (2005).
 25. Palminteri, S., Boraud, T., Lafargue, G., Dubois, B. & Pessiglione, M. Brain hemispheres selectively track the expected value of 
contralateral options. J Neurosci 29, 13465–13472 (2009).
 26. Palminteri, S., Kilford, E. J., Coricelli, G. & Blakemore, S.-J. The Computational Development of Reinforcement Learning during 
Adolescence. PLoS computational biology 12, e1004953 (2016).
 27. Baird, A. A. & Fugelsang, J. A. The emergence of consequential thought: evidence from neuroscience. Philosophical transactions of 
the Royal Society of London. Series B, Biological sciences 359, 1797–1804 (2004).
 28. Chiu, P. H., Lohrenz, T. M. & Montague, P. R. Smokers’ brains compute, but ignore, a fictive error signal in a sequential investment 
task. Nature neuroscience 11, 514–520 (2008).
 29. Moore, T. J., Glenmullen, J. & Mattison, D. R. Reports of pathological gambling, hypersexuality, and compulsive shopping associated 
with dopamine receptor agonist drugs. JAMA internal medicine 174, 1930–1933 (2014).
 30. Lofwall, M. R., Nuzzo, P. A., Campbell, C. & Walsh, S. L. Aripiprazole effects on self-administration and pharmacodynamics of 
intravenous cocaine and cigarette smoking in humans. Experimental and clinical psychopharmacology 22, 238–247 (2014).
 31. Jordan, S. et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European journal of 
pharmacology 441, 137–140 (2002).
 32. Tamminga, C. A. & Carlsson, A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Current drug 
targets CNS and neurological disorders 1, 141–147 (2002).
 33. Yasui-Furukori, N., Kaneda, A., Sugawara, N., Tomita, T. & Kaneko, S. Effect of adjunctive treatment with aripiprazole to atypical 
antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol 26, 806–812 (2012).
 34. Schlagenhauf, F. et al. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory 
dependent functional activation. Schizophr Res 118, 189–200 (2010).
 35. Suzuki, H., Gen, K. & Inoue, Y. An unblinded comparison of the clinical and cognitive effects of switching from first-generation 
antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol 
Psychiatry 35, 161–168 (2011).
 36. Wang, C., Zheng, D., Xu, J., Lam, W. & Yew, D. T. Brain damages in ketamine addicts as revealed by magnetic resonance imaging. 
Front Neuroanat 7, 23 (2013).
 37. Lee, B. J. et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with 
risperidone. Clin Psychopharmacol Neurosci 11, 60–66 (2013).
 38. Maat, A. et al. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. Eur 
Neuropsychopharmacol 24, 575–584 (2014).
 39. Yeh, C.-B. et al. Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia. Nord J Psychiatry 68, 
219–224 (2014).
 40. Kim, E. et al. The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: A dual 
[(11)C]raclopride and [(18)F]FDG imaging study with aripiprazole. Psychopharmacology 227, 221–229 (2013).
 41. Handley, R. et al. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. 
Hum Brain Mapp 34, 272–282 (2013).
 42. Bolstad, I. et al. No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and 
haloperidol. Frontiers in human neuroscience 9, 296 (2015).
 43. Zocchi, A., Fabbri, D. & Heidbreder, C. A. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse 
prefrontal cortex. Neuroscience letters 387, 157–161 (2005).
 44. Tanahashi, S., Yamamura, S., Nakagawa, M., Motomura, E. & Okada, M. Dopamine D2 and serotonin 5-HT1A receptors mediate 
the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology 62, 765–774 (2012).
 45. Wunderlich, K., Smittenaar, P. & Dolan, R. J. Dopamine enhances model-based over model-free choice behavior. Neuron 75, 
418–424 (2012).
 46. Worbe, Y. et al. Valence-dependent influence of serotonin depletion on model-based choice strategy. Molecular psychiatry 21, 
624–629 (2016).
 47. Doll, B. B., Bath, K. G., Daw, N. D. & Frank, M. J. Variability in Dopamine Genes Dissociates Model-Based and Model-Free 
Reinforcement Learning. The Journal of neuroscience 36, 1211–1222 (2016).
 48. Sharp, M. E., Foerde, K., Daw, N. D. & Shohamy, D. Dopamine selectively remediates’model-based’ reward learning: a computational 
approach. Brain 139, 355–364 (2016).
 49. Tanaka, S. C. et al. Serotonin differentially regulates short- and long-term prediction of rewards in the ventral and dorsal striatum. 
PloS one 2, e1333 (2007).
 50. Bortolozzi, A., Díaz-Mataix, L., Toth, M., Celada, P. & Artigas, F. In vivo actions of aripiprazole on serotonergic and dopaminergic 
systems in rodent brain. Psychopharmacology 191, 745–758 (2007).
 51. Graybiel, A. M. & Canales, J. J. The neurobiology of repetitive behaviors: clues to the neurobiology of Tourette syndrome. Adv Neurol 
85, 123–131 (2001).
 52. Albin, R. L. & Mink, J. W. Recent advances in Tourette syndrome research. Trends Neurosci 29, 175–182 (2006).
 53. Malison, R. T. et al. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette’s disorder. Am J Psychiatry 
152, 1359–1361 (1995).
 54. Gilbert, D. L. et al. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology 67, 1695–1697 (2006).
 55. Wong, D. F. et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo 
neurochemistry study with PET. Neuropsychopharmacology 33, 1239–1251 (2008).
 56. Minzer, K., Lee, O., Hong, J. J. & Singer, H. S. Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal 
cortex and striatum. J Neurol Sci 219, 55–61 (2004).
 57. Yoon, D. Y., Gause, C. D., Leckman, J. F. & Singer, H. S. Frontal dopaminergic abnormality in Tourette syndrome: a postmortem 
analysis. J Neurol Sci 255, 50–56 (2007).
 58. Xu, L. et al. Lack of genetic association of 5-HTR2A 102 T/C and -1438A/G polymorphisms with Tourette syndrome in a family-
based association study in a Chinese Han population. Asia-Pacific psychiatry 8, 87–91 (2016).
 59. Yi, M., Zhang, Y., Wang, Y., Su, N. & Liu, S. Association between the polymorphism of C861G (rs6296) in the serotonin 1B receptor 
gene and Tourette syndrome in Han Chinese people. Asia-Pacific psychiatry. doi:10.1111/appy.12196 (2015).
 60. Palminteri, S. & Pessiglione, M. Reinforcement learning and Tourette syndrome. International review of neurobiology 112, 131–153 
(2013).
 61. Maia, T. V. & Frank, M. J. From reinforcement learning models to psychiatric and neurological disorders. Nature neuroscience 14, 
154–162 (2011).
 62. Palminteri, S. et al. Dopamine-dependent reinforcement of motor skill learning: evidence from Gilles de la Tourette syndrome. Brain 
134, 2287–2301 (2011).
www.nature.com/scientificreports/
1 0SCIENTIFIC RepoRts | 7: 6292  | DOI:10.1038/s41598-017-06547-8
 63. Palminteri, S. et al. Pharmacological modulation of subliminal learning in Parkinson’s and Tourette’s syndromes. Proc Natl Acad Sci 
USA 106, 19179–19184 (2009).
 64. Pessiglione, M. et al. Subliminal instrumental conditioning demonstrated in the human brain. Neuron 59, 561–567 (2008).
 65. Delorme, C. et al. Enhanced habit formation in Gilles de la Tourette syndrome. Brain 139, 605–615 (2016).
 66. Leckman, J. F. et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc 
Psychiatry 28, 566–573 (1989).
 67. Welch, B. On the comparison of several mean values: an alternative approach. Biometrika 38, 330–336 (1951).
Acknowledgements
A.S. was supported by a Fondation pour la Recherche Médicale grant (grant number FDM20120624489). S.P. 
is supported by an ATIP-Avenir starting grant (R16069JS) and a Collaborative Research in Computational 
Neuroscience ANR-NSF grant (ANR-16- NEUC-0004). The study was supported by a grant from the Association 
Française du Syndrome de Gilles de la Tourette to Y.W. The funding agencies did not influence the content of the 
manuscript. The Institut d’Etude de la Cognition is supported financially by the LabEx IEC (ANR-10-LABX-0087 
IEC) and the IDEX PSL* (ANR-10-IDEX-0001-02 PSL*).
Author Contributions
A.S. performed the experiments, analysed the data, interpreted the results and wrote the manuscript. Y.W. 
designed the study, performed the experiment, interpreted the results and edited the manuscript. C.D. performed 
the experiments and edited the manuscript. G.C., R.G., T.W.R. interpreted the results and edited the manuscript. 
A.H. designed the study and interpreted the results. S.P. designed the study, analysed the data, interpreted the 
results and wrote the manuscript.
Additional Information
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
